McKesson (MCK) Earnings Date & Reports

Key Takeaways

• McKesson reported adjusted EPS (earnings per share) of $11.68 for the second quarter of fiscal 2027, up 18% year over year and above the consensus estimate of roughly $10.71.
• Consolidated revenue rose 8% to approximately $111 billion ($110.96 billion), topping the roughly $109.86 billion analyst consensus.
• The company raised its full-year fiscal 2027 adjusted EPS guidance to $45.60–$46.40, up from a prior range of $44.20–$45.00.
• Growth was led by specialty distribution and GLP-1 (glucagon-like peptide-1) medication volumes; GLP-1 distribution revenue reached $16 billion, up 26% year over year.
• Medical-Surgical Solutions adjusted operating profit declined 10%, reflecting lower contributions from the ambulatory care channel due to product mix.
• McKesson announced a roughly $1.4 billion minority investment in Option Care Health and completed its approximately $2.25 billion acquisition of Precision Medicine Group.
• For more on McKesson's Major News, Today's Price Move, Price Targets, and Forecast, explore Tickeron's dedicated MCK pages.
• Explore Trending AI Robots to see AI-driven trading strategies tracking stocks like McKesson.

Earnings Context and Why It Matters

McKesson Corporation (MCK) is one of the largest pharmaceutical distributors in the United States, and its quarterly results offer a window into broad healthcare supply-chain dynamics, including prescription volumes, specialty drug trends, and payer behavior. The fiscal second quarter, ended September 30, 2026, comes as demand for specialty therapies and GLP-1 medications continues to reshape the distribution landscape. Because McKesson operates on a fiscal year ending March 31, this report represents the midpoint of fiscal 2027 and is a key checkpoint for management's full-year outlook. Investors watch these results closely for evidence that growth in high-margin specialty and oncology services can offset persistent pressure from branded-to-generic conversions and branded pharmaceutical pricing.

Reported Results

McKesson delivered second-quarter fiscal 2027 adjusted EPS of $11.68, an 18% increase from $9.86 in the prior-year period and well above the consensus estimate of roughly $10.71. Consolidated revenue climbed 8% to approximately $111 billion ($110.96 billion), exceeding the analyst consensus of about $109.86 billion. On a GAAP (Generally Accepted Accounting Principles) basis, the company does not provide forward-looking guidance, citing difficulty in forecasting certain items.

Gross profit increased 10% to $3.9 billion, while operating profit rose 13% to $1.9 billion, driven by operating leverage and a lower share count. By segment, North American Pharmaceutical revenue grew 6% to $91.4 billion, with adjusted segment operating profit up 22% to $1.0 billion. Oncology & Multispecialty revenue jumped 24% to $15.0 billion, and Prescription Technology Solutions revenue rose 10% to $1.5 billion. Medical-Surgical Solutions revenue increased 5% to $3.1 billion, though its adjusted operating profit fell 10% to $225 million.

Management raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40, up from $44.20–$45.00 and above the consensus of approximately $44.66, citing strength across the business and confidence in execution.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for earnings-focused research and beyond. Consider exploring the AI Screener to complement your analysis of names like McKesson and other healthcare distributors.

Market Reaction and Investor Sentiment

McKesson shares reacted positively to the report, closing at $1,069.44, up approximately 7% on the session, as investors responded to the double beat and the upward revision to full-year guidance. The results reinforced sentiment that demand for specialty pharmaceuticals, oncology services, and GLP-1 therapies remains a durable growth engine for the company. Sentiment was further supported by the announced extension of McKesson's pharmaceutical distribution partnership with CVS Health through June 2032, as well as strategic moves into community-based specialty care. The main area of investor scrutiny remains the Medical-Surgical Solutions segment, where product mix pressured profitability even as revenue advanced.

Forward Outlook and Key Factors to Monitor

Following the guidance raise, attention shifts to McKesson's ability to sustain specialty-led momentum through the second half of fiscal 2027. The recently completed acquisition of Precision Medicine Group is expected to contribute approximately $0.10–$0.20 of adjusted EPS in fiscal 2027, with contributions weighted toward the fourth quarter, and management projects accretion of roughly $1.60–$1.80 by the end of year three.

Investors will also monitor the planned roughly $1.4 billion investment for a 49% stake in Option Care Health, which is expected to close in the first half of calendar 2027, as well as the ongoing separation of the Medical-Surgical Solutions business. On the demand side, GLP-1 volumes remain strong, though management noted quarter-to-quarter variability tied to payer dynamics and patient utilization.

Other factors worth watching include the pace of branded-to-generic conversions, branded pharmaceutical pricing adjustments, expense discipline, and continued share repurchases, which have helped reduce the diluted share count and support per-share growth. These elements will shape whether McKesson can maintain its operating leverage and deliver on its raised full-year outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations